Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of MN-08 tablets in Alzheimer's disease
CTR20223193Phase 2Active
- Sponsor
- Guangzhou Magpie Pharmaceutical
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nitronaphthazine in Alzheimer's disease (AD), sponsored by Guangzhou Magpie Pharmaceutical. Started Jan 2023; status: active.
02
Drugs
nitronaphthazine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20223193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223193.